Protalix BioTherapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.07 EPS, expectations were $-0.03. Protalix BioTherapeutics, Inc. isn’t one of the 30 most popular stocks among hedge ...
Earnings call Protalix reported 24% YTD revenue growth to $43.6M, despite a 1% YoY Q3 revenue dip due to partner inventory timing. Q3 net income was $2.4M, with a solid cash position of $29.4M. The ...
Protalix Biotherapeutics Inc. (NASDAQ:PLX) reported a net loss of $3.6 million for Q1 2025, translating to an earnings per share (EPS) of -$0.05, missing the forecasted $0.03. The company’s revenue ...
Good morning, ladies and gentlemen and welcome to the Protalix BioTherapeutics Fiscal Year 2023 Financial and Business Results Conference Call. As a reminder, this conference call is being recorded. I ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback